title: Epithelial sodium channel inhibition by amiloride on blood pressure and cardiovascular disease risk in young prehypertensives.
abstract: Overactivity of the epithelial sodium channel (ENaC) is considered to be one mechanism underlying obesity-related blood pressure (BP) elevation. In an open-labeled, nonplacebo-controlled clinical trial (Clinicaltrials.gov: NCT-01308983), the authors aimed to comprehensively evaluate the effects of amiloride monotherapy, an ENaC blocker, on BP and cardiovascular risk in young adults with prehypertension (n=17). The mean body mass index of participants was 28.45±1.30 kg/m(2) . Following 10 mg daily amiloride for 4 weeks, peripheral systolic BP (SBP), central SBP, and carotid-radial pulse wave velocity were significantly reduced by -7.06±2.25 mm Hg, -7.68±2.56 mm Hg, and -0.72±0.33 m/s, respectively, whereas flow-mediated dilation was significantly increased by 2.2±0.9%. Following amiloride monotherapy for 4 weeks, a significant increase in serum aldosterone was observed (5.85±2.45 ng/dL). ENaC inhibition by amiloride may be used as an early intervention to halt the progression to full hypertension and cardiovascular disease in young adults with prehypertension.
authors.affiliation: Georgia Prevention Center, Medical College of Georgia, Georgia Regents University, Augusta, GA; Department of Internal Medicine, Medical College of Georgia, Georgia Regents University, Augusta, GA.
authors.forename: Jigar
authors.initials: J
authors.lastname: Bhagatwala
authors.forename: Ryan A
authors.initials: RA
authors.lastname: Harris
authors.forename: Samip J
authors.initials: SJ
authors.lastname: Parikh
authors.forename: Haidong
authors.initials: H
authors.lastname: Zhu
authors.forename: Ying
authors.initials: Y
authors.lastname: Huang
authors.forename: Ishita
authors.initials: I
authors.lastname: Kotak
authors.forename: Nichole
authors.initials: N
authors.lastname: Seigler
authors.forename: Gary L
authors.initials: GL
authors.lastname: Pierce
authors.forename: Brent M
authors.initials: BM
authors.lastname: Egan
authors.forename: Yanbin
authors.initials: Y
authors.lastname: Dong
mesh_terms: D000328:Adult; D001741:Black or African American; D000584:Amiloride / Q000494:pharmacology* / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects* / Q000502:physiology*; D001916:Brachial Artery / Q000502:physiology; D002318:Cardiovascular Diseases / Q000453:epidemiology*; D018450:Disease Progression; D062686:Epithelial Sodium Channel Blockers / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D058246:Prehypertension / Q000150:complications* / Q000188:drug therapy / Q000208:ethnology; D063177:Pulse Wave Analysis; D012039:Regional Blood Flow / Q000187:drug effects / Q000502:physiology; D012307:Risk Factors; D016896:Treatment Outcome; D044465:White People
chemical_list: D062686:Epithelial Sodium Channel Blockers; D000584:Amiloride